Zorevunersen

Stoke Therapeutics announced the EMPEROR phase 3 trial for zorevunersen in Dravet syndrome, targeting 150 patients globally. The 60-week study aims to reduce major motor seizure frequency and improve cognition and behavior. Zorevunersen, showing promise in earlier trials, could offer a disease-modifying treatment, with data expected by end of 2027.

Analyst Andrew Fein maintained a Buy rating on Stoke Therapeutics (STOK) with a $35 price target, citing global regulatory alignment on the Emperor trial for zorevunersen, promising Phase 1/2a data showing significant seizure reduction in Dravet syndrome, and the trial's robust design. Chardan Capital also reiterated a Buy rating with a $24 target.

4 analysts rated Stoke Therapeutics (STOK) with a mix of bullish and bearish views. The average 12-month price target is $25.75, with a high of $35.00 and a low of $22.00, showing a 2.2% drop from the previous average. Stoke Therapeutics focuses on RNA-based medicines for severe diseases, with notable revenue growth but below industry averages in some financial metrics.

Stoke Therapeutics aligns with FDA, EMA, and PMDA for Phase 3 EMPEROR study of zorevunersen, targeting Dravet syndrome in children. The study aims to reduce major motor seizure frequency and improve cognition and behavior, with Phase 3 initiation planned for mid-2025. Zorevunersen received FDA Breakthrough Therapy designation, indicating potential for significant improvement over existing treatments.

Stoke Therapeutics announced alignment with FDA, EMA, and PMDA on the Phase 3 EMPEROR study design for zorevunersen, targeting Dravet syndrome. The study will assess seizure frequency reduction and cognitive/behavioral improvements in children and adolescents. FDA Breakthrough Therapy designation accelerates development, with Phase 3 initiation planned for mid-2025.

Stoke Therapeutics finalized the Phase 3 EMPEROR study protocol for zorevunersen, targeting Dravet syndrome treatment. The study, starting mid-2025, will assess seizure reduction and cognitive improvements in children and adolescents. Zorevunersen, with FDA Breakthrough Therapy Designation, showed an 87% median seizure reduction in earlier studies and was well tolerated.

Stoke Therapeutics aligns with global regulators for Phase 3 EMPEROR study of zorevunersen, targeting Dravet syndrome treatment by mid-2025. The study aims to reduce seizures and improve cognitive functions in children, addressing a significant market. Stoke focuses on RNA medicine for genetic disorders, with a current market cap of $608.6M.

Stoke Therapeutics finalized its EMPEROR Phase 3 study protocol for zorevunersen in treating Dravet syndrome, following regulatory alignment. The study, starting mid-2025, will assess seizure frequency reduction and cognitive/behavioral improvements in children and adolescents.

Stoke Therapeutics aligns with FDA, EMA, and PMDA for a Phase 3 study of zorevunersen, aiming to treat Dravet syndrome by reducing seizures and improving cognition and behavior in children and adolescents. The study, set to start mid-2025, targets a 52-week evaluation with data expected by end of 2027.